Prognostic Value of Unipolar and Bipolar Low Voltage Areas in Predicting Outcomes After Ventricular Tachycardia Ablation in Patients with Non-Ischemic Cardiomyopathy and Heart Failure
Abstract Body (Do not enter title and authors here): Background: Non-ischemic cardiomyopathy (NICM) patients with heart failure (HF) undergoing ventricular tachycardia (VT) ablation are at risk for long-term HF events. Left ventricular (LV) endocardial unipolar (Uni) and/or bipolar (Bi) low voltage areas (LVA) at ablation indicate abnormal myocardium, and their extent may predict HF events. Objective: To evaluate and compare the prognostic ability of endocardial Uni-LVA and Bi-LVA for the prediction of HF outcomes in NICM patients undergoing VT ablation. Methods: NICM and HF patients undergoing VT ablation between Jan 2020 and Dec 2023 at the Hospital of the University of Pennsylvania were included. Exclusions were ARVC, HCM, valvular disease, prior cardiac surgery. Uni-LVA was defined as <8.27mV and Bi-LVA <1.5mV during sinus/paced rhythm. Patients were followed at 6 weeks post-ablation, then at 6-month intervals. The HF outcomes included death, LVAD implant, heart transplant, or HF hospitalization. Patients were grouped into mild, moderate, and severe tertiles based on the extent of Uni-LVA and Bi-LVA. The association between tertiles and HF outcome was assessed by Cox regression, adjusted for age, sex, CKD, and LVEF. Results: A total of 137 patients with NICM and HF (mean age 62±12 years; 22.6% women) underwent VT ablation and LV endocardial voltage mapping. Of those, 129 had HFrEF (LVEF 30.5±10.8) and 8 had HFpEF (LVEF 56.5±4.4). Median Bi-LVA was 12.9% [IQR 5.4, 22.5] of the total LV endocardial surface. Bi-LVA tertiles were <8% (mild), 8-18.5% (moderate), >18.5% (severe). Median Uni-LVA was 50.1% [IQR 27.8, 76.5] of the total endocardial LV surface. Uni-LVA tertiles were <35% (mild), 35–68% (moderate), >68% (severe). HF outcomes occurred in 51 (37.2%) patients over a median follow-up of 2.6 years [IQR 1.8, 4.6]. HF outcome incidence was similar between mild Bi-LVA (24.4%, reference) and moderate Bi-LVA (30.4%, HR=0.77, 95%CI: 0.34–1.74, p=0.5), but significantly higher in severe Bi-LVA (56.5%, HR=2.8, 95%CI: 1.3–5.7, p=0.005). HF outcome incidence was 13.3% in mild Uni-LVA (reference), and significantly increased in moderate Uni-LVA (41.3%, HR=2.96, 95%CI: 1.1–7.6, p=0.02) and severe Uni-LVA (56.5%, HR=4.4, 95%CI: 1.7–10.9, p<0.001). Conclusions: The extent of endocardial LVA, particularly unipolar abnormalities, noted during VT ablation in NICM patients is a prognostic indicator for late HF outcomes. Even moderate degrees of Uni-LVA are associated with a threefold increase in the risk of late HF outcomes.
Afzalian, Arian
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Tschabrunn, Cory
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Guandalini, Gustavo
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Enriquez, Andres
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Garcia, Fermin
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Riley, Michael
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Lin, David
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Schaller, Robert
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Nazarian, Saman
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Callans, David
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Supple, Gregory
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Oraii, Alireza
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Kumareswaran, Ramanan
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Dixit, Sanjay
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Frankel, David
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Marchlinski, Francis
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Rodriguez-queralto, Oriol
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Hanumanthu, Balaram Krishna
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Zado, Erica
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Shivamurthy, Poojita
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Markman, Timothy
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Hyman, Matthew
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Peters, Carli
( Hospital of University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Author Disclosures:
Arian Afzalian:DO NOT have relevant financial relationships
| Cory Tschabrunn:No Answer
| Gustavo Guandalini:No Answer
| Andres Enriquez:No Answer
| Fermin Garcia:No Answer
| Michael Riley:DO NOT have relevant financial relationships
| David Lin:No Answer
| Robert Schaller:DO NOT have relevant financial relationships
| Saman Nazarian:DO have relevant financial relationships
;
Consultant:Dyne Pharmaceuticals:Active (exists now)
; Research Funding (PI or named investigator):ADAS Software:Active (exists now)
; Research Funding (PI or named investigator):Biosense Webster:Past (completed)
; Consultant:Biosense Webster:Active (exists now)
| David Callans:DO have relevant financial relationships
;
Independent Contractor:Biosense:Active (exists now)
; Independent Contractor:Biotronik:Active (exists now)
; Independent Contractor:Abbott Medical:Active (exists now)
; Independent Contractor:Boston Scientific:Active (exists now)
| Gregory Supple:DO NOT have relevant financial relationships
| Alireza Oraii:DO NOT have relevant financial relationships
| Ramanan Kumareswaran:No Answer
| Sanjay Dixit:DO NOT have relevant financial relationships
| David Frankel:DO have relevant financial relationships
;
Consultant:Biosense Webster:Active (exists now)
; Consultant:Huxley Medical:Past (completed)
; Research Funding (PI or named investigator):Biosense Webster:Active (exists now)
; Speaker:Medtronic:Active (exists now)
| Francis Marchlinski:No Answer
| Oriol Rodriguez-Queralto:DO NOT have relevant financial relationships
| Balaram Krishna Hanumanthu:DO NOT have relevant financial relationships
| Erica Zado:DO NOT have relevant financial relationships
| Poojita Shivamurthy:DO NOT have relevant financial relationships
| Timothy Markman:DO have relevant financial relationships
;
Consultant:Medtronic:Active (exists now)
; Consultant:Johnson and Johnson:Active (exists now)
; Consultant:Abbott:Active (exists now)
; Consultant:Boston Scientific:Active (exists now)
| Matthew Hyman:DO NOT have relevant financial relationships
| Carli Peters:No Answer